GlassScriptPhysician profile
Susheel Dua
NPI 1467598904
$36,320.28
in general payments reported to CMS, 2019-2025
29 companies · $785 in 2025
The $785 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $7,279 · 2021: $632 · 2022: $8,942 · 2023: $664 · 2024: $1,109 · 2025: $785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,558.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,557.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanos Medical | $29,246.39 | 2019-2025 | Standard Rf Disposables, Generator |
| Abbott Laboratories | $2,128.89 | 2019-2025 | Proclaim, Eterna |
| Boston Scientific Corporation | $1,383.75 | 2019-2025 | Wavewriter Alpha Prime 16, General - Pain Management, Intracept |
| Collegium Pharmaceutical, INC. | $973.11 | 2019-2025 | Belbuca, Xtampza |
| Medtronic, INC. | $316.36 | 2021-2024 | Intellis Adaptivestim, Accurian |
| Nevro Corp. | $311.13 | 2019-2024 | Senza |
| Spr Therapeutics, INC | $248.13 | 2019-2024 | Sprint Pns System |
| Abbvie INC. | $226.03 | 2023-2025 | Botox |
| Averitas Pharma INC. | $203.11 | 2024 | Qutenza |
| Medtronic USA, INC. | $173.22 | 2019 | |
| Forte Bio-Pharma LLC | $162.35 | 2020-2021 | |
| Allergan, INC. | $144.58 | 2019-2021 | |
| Mdd US Operations, LLC | $129.66 | 2019-2020 | |
| Pfizer INC. | $84.44 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $84.19 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $61.78 | 2020-2021 | |
| Sentynl Therapeutics, INC. | $54.18 | 2019 | |
| Tersera Therapeutics LLC | $51.52 | 2019 | |
| Merz Pharmaceuticals, LLC | $49.33 | 2023-2025 | Xeomin |
| Novartis Pharmaceuticals Corporation | $49.00 | 2019 | |
| Daiichi Sankyo INC. | $44.14 | 2019 | |
| Merck Sharp & Dohme LLC | $35.12 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $32.84 | 2024 | |
| Virtus Pharmaceuticals LLC | $29.27 | 2023 | Levorphanol Tartrate |
| Pacira Pharmaceuticals Incorporated | $24.09 | 2025 | Iovera, Zilretta |
| Grt US Holding, INC. | $22.77 | 2020 | |
| Flower Orthopedics Coporation | $20.24 | 2021 | |
| Biodelivery Sciences International, INC. | $17.53 | 2020 | |
| Redhill Biopharma INC. | $13.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susheel Dua listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.